All In Biotech

Drug Trial Radar · NCT02081378

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

326

Actual

Start

Apr 24, 2014

Primary completion

Jun 3, 2021

Study completion Mar 14, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic leukemia (Ph+ ALL) patients who are relapsed or refractory to or are intolerant of Tyrosine kinase inhibitors (TKIs), and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.

Conditions

  • Chronic Myelogenous Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Interventions

  • Asciminib (ABL001)Drug

    Asciminib was be administered orally in a dose escalation schedule.

  • NilotinibDrug

    Asciminib and Nilotinib was administered orally in CML patients

  • ImatinibDrug

    Asciminib and imatinib was administered orally in CML patients

  • DasatinibDrug

    Asciminib and dasatinib was administered orally in CML patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatmentTime frame: First Cycle is 28 days

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • Dana Farber Cancer Institute Hematology / Oncology

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center SC

    Ann Arbor, Michigan

  • Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering

    New York, New York

  • Oregon Health Sciences University SC-6

    Portland, Oregon

  • University of Texas/MD Anderson Cancer Center UT MD Anderson

    Houston, Texas

  • Huntsman Cancer Institute SC

    Salt Lake City, Utah

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Paris, Cedex 10, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Jena, Germany

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Kobe, Hyōgo, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, Seocho Gu, South Korea

  • Novartis Investigative Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.